<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03295981</url>
  </required_header>
  <id_info>
    <org_study_id>28229</org_study_id>
    <nct_id>NCT03295981</nct_id>
  </id_info>
  <brief_title>Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone</brief_title>
  <official_title>Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orthopaedic Research and Education Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Louis University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the clinical study is to investigate whether the local delivery of&#xD;
      bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone&#xD;
      coming back to the same location. The hypothesis is that the local administration of&#xD;
      bisphosphonate will decrease the rate of the tumor returning compared to traditional&#xD;
      aggressive surgical removal of the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the clinical study is to investigate whether the local delivery of&#xD;
      bisphosphonate (BP-loaded PMMA bone cement) as a surgical adjuvant can decrease the local&#xD;
      recurrence rate of giant cell tumor (GCT) of bone. The investigators will evaluate whether&#xD;
      bisphosphonate as a surgical adjuvant improves secondary outcomes, such as pain, function,&#xD;
      fever, or wound complications. The hypothesis is that the local administration of&#xD;
      bisphosphonate will decrease the recurrence rate of GCT compared to traditional aggressive&#xD;
      intralesional curettage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The endpoint for patient participation will be local recurrence</measure>
    <time_frame>Followed for 2 years postoperatively for study end points</time_frame>
    <description>Local recurrence of giant cell tumor of bone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MSTS Score</measure>
    <time_frame>Followed for 2 years postoperatively for study end points</time_frame>
    <description>The Musculoskeletal Tumor Society (MSTS) scoring system is a validated and well-accepted functional scoring system used in orthopaedic oncology research</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical site infection</measure>
    <time_frame>Follow-ups will consist of clinical visits. The clinical visits will be at 2 weeks postoperatively, 6 weeks postoperatively, and then every three months for the first two years after surgery.</time_frame>
    <description>The surgical site will be assessed for a surgical site infection (SSI) as defined by CDC guidelines after surgery and during scheduled follow-up as outlined in time frame below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound healing</measure>
    <time_frame>Follow-ups will consist of clinical visits. The clinical visits will be at 2 weeks postoperatively, 6 weeks postoperatively, and then every three months for the first two years after surgery.</time_frame>
    <description>The surgical site will be assessed after surgery and during scheduled follow-up as outlined in time frame below for wound healing issues/concerns.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential bisphosphonate complications related to systemic administration</measure>
    <time_frame>Followed for 2 years postoperatively for study end points</time_frame>
    <description>Patients will be followed for atypical femur fractures and avascular necrosis (AVN) of jaw</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Giant Cell Tumor of Bone</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The surgical procedure for all patients will include extensive curettage of the lesion to remove macroscopic tumor, high-speed burring of the residual cavity, adjuvant treatment to the residual cavity, followed by packing of the cavity with either polymethylmethacrylate (PMMA) bone cement (Simplex P; Stryker, Mahwah, New Jersey) alone or bone cement with subchondral allograft bone graft. The choice of cavity reconstruction will be at the discretion of the treating surgeon. Traditional local adjuvants (argon beam coagulation, phenol, ethanol, or cryotherapy) will be used depending on surgeon preference. In addition to the above standard treatment, the patients will be randomized into one of two study arms. In Arm 1, the control group, no additional local therapy will be utilized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bisphosphonate group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Arm 2, the bisphosphonate group, 4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <description>4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement</description>
    <arm_group_label>Bisphosphonate group</arm_group_label>
    <other_name>zoledronate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary benign GCT of bone&#xD;
&#xD;
          -  Lesion located in an extremity&#xD;
&#xD;
          -  Lesion amenable to reconstruction (intralesional curettage) defined as having at least&#xD;
             one intact column of bone after removal&#xD;
&#xD;
          -  No previous systemic bisphosphonate or denosumab therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recurrent GCT of bone&#xD;
&#xD;
          -  Non-extremity location&#xD;
&#xD;
          -  Lesion too extensive for intralesional treatment, either due to bone loss, joint&#xD;
             invasion, or large soft tissue component&#xD;
&#xD;
          -  Children and pregnancy&#xD;
&#xD;
          -  Previous systemic bisphosphonate or denosumab therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Dawson, RN</last_name>
    <phone>314-577-8527</phone>
    <email>sarah.dawson@health.slu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marsha Steffen, RN</last_name>
    <phone>314-577-8904</phone>
    <email>marsha.steffen@health.slu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Crawford</last_name>
      <email>BrookeCrawford@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Brooke Crawford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julian Dilley</last_name>
      <email>jedilley@indiana.edu</email>
    </contact>
    <investigator>
      <last_name>L.Daniel Wurtz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Smith</last_name>
      <email>tammy-smith@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Bradshaw</last_name>
      <email>sbradshaw2@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Kyle Sweeney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaishali Laljani</last_name>
      <email>vparikh2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Levin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Greenberg, MD</last_name>
      <phone>314-577-8904</phone>
      <email>david.greenberg@health.slu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Dawson, RN</last_name>
      <phone>(314) 577-8527</phone>
      <email>sarah.dawson@health.slu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariel Brotherton, MA</last_name>
      <email>abrother@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Cynthia Emory, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Keaney, MPH</last_name>
      <email>keaneyh@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Kierstyn Hayden</last_name>
      <email>haydenk2@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Lukas Nystrom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathy Edge</last_name>
      <email>Kathy-edge@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremy White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Wetzel</last_name>
      <email>wetzelr@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Gundle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny-Singer Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Finamore, MS</last_name>
      <email>angela.finamore@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Lisa Ercolano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Gonzalez</last_name>
      <email>kgonzalez@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>John Neilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Coordinator, Sarcoma</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>43022</phone_ext>
    </contact>
    <investigator>
      <last_name>Robert Turcotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2017</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Louis University</investigator_affiliation>
    <investigator_full_name>David Greenberg, MD;; Associate Professor</investigator_full_name>
    <investigator_title>Associate Professor Orthopaedic Surgery Saint Louis University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Giant Cell Tumors</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Giant Cell Tumor of Bone</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

